EE03783B1 - Farmatseutiline kompositsioon epitelioomide raviks ja antikeha või antikeha molekuli kasutamine - Google Patents

Farmatseutiline kompositsioon epitelioomide raviks ja antikeha või antikeha molekuli kasutamine

Info

Publication number
EE03783B1
EE03783B1 EE9800164A EE9800164A EE03783B1 EE 03783 B1 EE03783 B1 EE 03783B1 EE 9800164 A EE9800164 A EE 9800164A EE 9800164 A EE9800164 A EE 9800164A EE 03783 B1 EE03783 B1 EE 03783B1
Authority
EE
Estonia
Prior art keywords
antibody
epitheliomas
treatment
pharmaceutical composition
antibody molecule
Prior art date
Application number
EE9800164A
Other languages
English (en)
Other versions
EE9800164A (et
Inventor
Heider Karl-Heinz
Adolf G�nther
Ostermann Elinborg
Patzelt Erik
Sproll Marlies
Original Assignee
Boehringer Ingelheim International Gmbh
Forschungszentrum Karlsruhe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Boehringer Ingelheim International Gmbh, Forschungszentrum Karlsruhe Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of EE9800164A publication Critical patent/EE9800164A/et
Publication of EE03783B1 publication Critical patent/EE03783B1/et

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
EE9800164A 1995-12-06 1996-12-05 Farmatseutiline kompositsioon epitelioomide raviks ja antikeha või antikeha molekuli kasutamine EE03783B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17
PCT/EP1996/005448 WO1997021104A1 (de) 1995-12-06 1996-12-05 Verfahren zur diagnose und therapie von plattenepithelkarzinomen

Publications (2)

Publication Number Publication Date
EE9800164A EE9800164A (et) 1998-12-15
EE03783B1 true EE03783B1 (et) 2002-06-17

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800164A EE03783B1 (et) 1995-12-06 1996-12-05 Farmatseutiline kompositsioon epitelioomide raviks ja antikeha või antikeha molekuli kasutamine

Country Status (26)

Country Link
EP (1) EP0865609B1 (et)
JP (1) JP2000502067A (et)
KR (1) KR100473824B1 (et)
CN (1) CN1151377C (et)
AR (1) AR004360A1 (et)
AT (1) ATE235056T1 (et)
AU (1) AU726704B2 (et)
BG (1) BG62985B1 (et)
BR (1) BR9611901A (et)
CA (1) CA2239709A1 (et)
CO (1) CO4520233A1 (et)
CZ (1) CZ174198A3 (et)
DE (1) DE59610248D1 (et)
DK (1) DK0865609T3 (et)
EE (1) EE03783B1 (et)
ES (1) ES2190484T3 (et)
HK (1) HK1011560A1 (et)
MX (1) MX9804459A (et)
NO (1) NO319903B1 (et)
NZ (1) NZ324314A (et)
PL (1) PL184521B1 (et)
PT (1) PT865609E (et)
SK (1) SK284378B6 (et)
TR (1) TR199801027T2 (et)
UY (1) UY24389A1 (et)
WO (1) WO1997021104A1 (et)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
HUP0400030A3 (en) * 2001-05-18 2006-02-28 Boehringer Ingelheim Pharma Antibodies specific for cd44v6
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
KR20130042466A (ko) * 2010-02-04 2013-04-26 유니버시티 오브 마이애미 두경부 편평 세포 암종의 치료에 사용하기 위한 ｃｄ44에 대한 단클론 항체
US9218450B2 (en) * 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
WO2019161528A1 (en) * 2018-02-22 2019-08-29 Abmart Shanghai Co., Ltd. Therapeutic antibody and uses thereof
WO2023227644A2 (en) 2022-05-25 2023-11-30 Akiram Therapeutics Ab Binding protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69406664T2 (de) * 1993-06-18 1998-06-04 Biotie Therapies Oy Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6
EP0767378A1 (de) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Diagnose und Analyse von Magenkarzinomen
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
KR19990071952A (ko) 1999-09-27
NO319903B1 (no) 2005-09-26
NO982588L (no) 1998-08-05
EE9800164A (et) 1998-12-15
CZ174198A3 (cs) 1999-02-17
HK1011560A1 (en) 1999-07-16
PT865609E (pt) 2003-08-29
MX9804459A (es) 1998-09-30
SK284378B6 (sk) 2005-02-04
NO982588D0 (no) 1998-06-05
CN1207811A (zh) 1999-02-10
AR004360A1 (es) 1998-11-04
CA2239709A1 (en) 1997-06-12
ATE235056T1 (de) 2003-04-15
JP2000502067A (ja) 2000-02-22
UY24389A1 (es) 2001-10-25
BR9611901A (pt) 1999-03-02
EP0865609B1 (de) 2003-03-19
PL327066A1 (en) 1998-11-23
AU1177397A (en) 1997-06-27
AU726704B2 (en) 2000-11-16
BG62985B1 (bg) 2000-12-29
CN1151377C (zh) 2004-05-26
DK0865609T3 (da) 2003-06-23
KR100473824B1 (ko) 2005-09-30
DE59610248D1 (de) 2003-04-24
WO1997021104A1 (de) 1997-06-12
ES2190484T3 (es) 2003-08-01
CO4520233A1 (es) 1997-10-15
PL184521B1 (pl) 2002-11-29
BG102513A (en) 1999-02-26
NZ324314A (en) 2000-02-28
EP0865609A1 (de) 1998-09-23
SK73698A3 (en) 1999-01-11
TR199801027T2 (xx) 1998-10-21

Similar Documents

Publication Publication Date Title
BR9611986A (pt) Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
NO962606L (no) Farmasöytisk sammensetning
BR1100824A (pt) Composto e composição farmacêutica
BR9500784A (pt) Composto e formulação farmacêutica
BR9504060A (pt) Composto e formulação farmacêutica
NO954146D0 (no) Belagte farmasöytiske preparater
BR9607317A (pt) Peptídios e composição farmacêutica
BR9607318A (pt) Peptidos e composição farmacêutica
BR9602705A (pt) Composto composição farmacéutica processo para a preparação de um composto e uso
KR950703566A (ko) 티에노디아제핀 화합물 및 그의 의약 용도[thienodiazepine compound and medicinal use thereof]
FI944832A (fi) Farmaseuttinen koostumus
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE03783B1 (et) Farmatseutiline kompositsioon epitelioomide raviks ja antikeha või antikeha molekuli kasutamine
BR9610733A (pt) Composto processos para a preparação do mesmo e para o tratamento de um mamífero composição farmacêutica e utilização de um composto
ITMI932540A0 (it) Composizione farmaceutica
LV11727A (lv) Farmaceitiska kompozicija
FI973229A0 (fi) Uusi farmaseuttinen koostumus
BR9507768A (pt) Composição farmacêutica
BR9612206A (pt) Composto uso do composto composição farmacêutica processo para preparação do composto e para o tratamento da dor
FI973280A0 (fi) Farmaseuttinen koostumus
FI964113A (fi) Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö
BR9610851A (pt) Composto processo de preparação de composto medicamento composição farmacêuticas e utilização do composto
LV10579A (lv) Farmaceitiska kompozicija
BR9606066A (pt) Composto e formulação farmacêutica

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

MM4A Lapsed by not paying the annual fees

Effective date: 20051205